What is the appropriate infliximab (Remicade) dosing schedule for induction and maintenance in ulcerative colitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Infliximab Dosing for Ulcerative Colitis

For moderate-to-severe ulcerative colitis, administer infliximab 5 mg/kg intravenously at weeks 0,2, and 6 for induction, followed by 5 mg/kg every 8 weeks for maintenance. 1

Standard Dosing Regimen

Induction Phase

  • 5 mg/kg IV at weeks 0,2, and 6 1
  • This applies to both adults and pediatric patients ≥6 years old
  • Clinical response typically assessed at week 8

Maintenance Phase

  • 5 mg/kg IV every 8 weeks after completing induction 1
  • Continue indefinitely for sustained remission
  • Combination with thiopurines (azathioprine or mercaptopurine) is more effective than monotherapy and should be used for at least 6-12 months 2

Acute Severe Ulcerative Colitis (ASUC)

In hospitalized patients with steroid-refractory ASUC, use standard 5 mg/kg dosing initially. The evidence does not support routine use of intensified dosing (10 mg/kg or accelerated schedules) upfront 3, 4.

When to Consider Accelerated Dosing

If patients fail to respond adequately after 3-5 days:

  • Administer an early repeat infusion (accelerated dosing) 5
  • Particularly beneficial in patients with:
    • Low albumin (<35 g/L) 5
    • High CRP (>50 mg/L) 5
    • Severe endoscopic disease 5

Critical caveat: Accelerated dosing should only occur after colorectal surgical review confirms colectomy is not immediately required 5. The 2024 PREDICT-UC trial found no significant difference between 10 mg/kg and 5 mg/kg initial dosing for day 7 clinical response (65% vs 61%, p=0.62) 4. However, patients with high infliximab clearance (≥0.62 L/day) may benefit from higher initial doses 6.

Monitoring in ASUC

  • Day 3 serum infliximab level ≤57.9 μg/mL predicts colectomy risk (83% sensitivity, 97% negative predictive value) 6
  • Consider therapeutic drug monitoring to guide dose intensification decisions
  • Median time to response is 4 days; failure to respond by day 7 warrants surgical consultation 7

Efficacy Data

The ACT 1 and ACT 2 trials established infliximab's efficacy 8:

  • Week 8 clinical response: 61-69% (vs 29-37% placebo)
  • Week 54 clinical response: 44-45% (vs 20% placebo)
  • Maintenance remission rates: Approximately 40% at 8-9 months 3, 9

In pediatric UC, 73.3% achieved week 8 response, with 28.6% overall remission at week 54 using every-8-week maintenance 10.

Loss of Response and Dose Escalation

Annual loss of response occurs in 10% of patients (higher at 13.6% in the first year) 11. When loss of response occurs:

  • Consider dose escalation to 10 mg/kg every 8 weeks 1
  • Alternatively, shorten interval to every 4-6 weeks (though this increases infection risk) 1
  • Check infliximab trough levels and antibodies to guide decision
  • Dose escalation regains clinical benefit in 72% of patients 11

Common Pitfalls

  1. Delaying surgery in ASUC: Do not continue multiple infliximab doses if no response by day 7. Prolonged medical therapy before colectomy increases postoperative complications 5

  2. Sequential rescue therapy: Avoid switching from infliximab to ciclosporin (or vice versa) in ASUC—this increases serious adverse events without clear benefit 5

  3. Inadequate combination therapy: Failing to add thiopurines during induction reduces efficacy and increases immunogenicity 2, 5

  4. Premature discontinuation: Patients who don't respond by week 14 are unlikely to benefit from continued dosing and should be considered for alternative therapy 1

Safety Considerations

Serious adverse events occur at similar rates to placebo in controlled trials 2, 8. However:

  • Higher doses and more frequent dosing increase infection risk 1
  • Screen for tuberculosis, hepatitis B/C, and HIV before initiating 1
  • Provide Pneumocystis jirovecii prophylaxis when combining with corticosteroids and thiopurines 5

References

Research

Infliximab for induction and maintenance therapy for ulcerative colitis.

The New England journal of medicine, 2005

Research

Systematic review: Infliximab therapy in ulcerative colitis.

Alimentary pharmacology & therapeutics, 2007

Research

Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.